Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations
Current standards of treatment of endocrine-dependent cancers (breast cancer (BC), prostate cancer) imply sequential use of endocrine therapy and cytotoxic agents: it is believed, that steroid hormone antagonists cease the division of transformed cells and therefore make them resistant to other ther...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2016-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/493 |
| _version_ | 1826557251995828224 |
|---|---|
| author | E. N. Imyanitov |
| author_facet | E. N. Imyanitov |
| author_sort | E. N. Imyanitov |
| collection | DOAJ |
| description | Current standards of treatment of endocrine-dependent cancers (breast cancer (BC), prostate cancer) imply sequential use of endocrine therapy and cytotoxic agents: it is believed, that steroid hormone antagonists cease the division of transformed cells and therefore make them resistant to other therapeutic modalities. It is important to recognize that conceptual investigations in this field were carried out dozens of years ago, and often involved relatively non-efficient drugs, imperfect laboratory tests, etc. There are several recent examples of combined use of endocrine therapy and other compounds. The addition of docetaxel (6 cycles) to androgen deprivation resulted in significant improvement of overall survival in men with metastatic prostate cancer. Clinical trial involving the combined use of exemestane and everolimus demonstrated promising results. There are ongoing studies on inhibitors of cycline-dependent kinases. Use of these drugs in the beginning of endocrine therapy may significantly delay resistance to the antagonists of estrogen signaling. |
| first_indexed | 2024-04-10T01:56:03Z |
| format | Article |
| id | doaj.art-027f1b31651a446b92aab8f305673103 |
| institution | Directory Open Access Journal |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| last_indexed | 2025-03-14T08:25:38Z |
| publishDate | 2016-09-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj.art-027f1b31651a446b92aab8f3056731032025-03-02T13:05:33ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272016-09-01122465110.17650/1994-4098-2016-12-2-46-51498Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinationsE. N. Imyanitov0N. N. Petrov Research Institute of Oncology, Ministry of Health of RussiaCurrent standards of treatment of endocrine-dependent cancers (breast cancer (BC), prostate cancer) imply sequential use of endocrine therapy and cytotoxic agents: it is believed, that steroid hormone antagonists cease the division of transformed cells and therefore make them resistant to other therapeutic modalities. It is important to recognize that conceptual investigations in this field were carried out dozens of years ago, and often involved relatively non-efficient drugs, imperfect laboratory tests, etc. There are several recent examples of combined use of endocrine therapy and other compounds. The addition of docetaxel (6 cycles) to androgen deprivation resulted in significant improvement of overall survival in men with metastatic prostate cancer. Clinical trial involving the combined use of exemestane and everolimus demonstrated promising results. There are ongoing studies on inhibitors of cycline-dependent kinases. Use of these drugs in the beginning of endocrine therapy may significantly delay resistance to the antagonists of estrogen signaling.https://ojrs.abvpress.ru/ojrs/article/view/493breast cancerprostate cancerendocrine therapyinhibitors of cyclin-dependent kinasescdkmtor |
| spellingShingle | E. N. Imyanitov Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations Опухоли женской репродуктивной системы breast cancer prostate cancer endocrine therapy inhibitors of cyclin-dependent kinases cdk mtor |
| title | Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations |
| title_full | Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations |
| title_fullStr | Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations |
| title_full_unstemmed | Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations |
| title_short | Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations |
| title_sort | evolution of systemic treatment for hormone sensitive breast cancer from sequential use of single agents to the upfront administration of drug combinations |
| topic | breast cancer prostate cancer endocrine therapy inhibitors of cyclin-dependent kinases cdk mtor |
| url | https://ojrs.abvpress.ru/ojrs/article/view/493 |
| work_keys_str_mv | AT enimyanitov evolutionofsystemictreatmentforhormonesensitivebreastcancerfromsequentialuseofsingleagentstotheupfrontadministrationofdrugcombinations |